• Jue Wang, Sai Gu, and Bo Qin.
• Department of Gastroenterology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
• Medicine (Baltimore). 2021 May 21; 100 (20): e26045e26045.

ObjectiveThe effect of Helicobacter pylori (H pylori) eradication therapy in functional dyspepsia (FD) patients was inconsistent in previously published randomized controlled trials. Therefore, we performed a comprehensive protocol for systematic review and meta-analysis in order to assess whether H pylori eradication therapy benefits patients with FD.MethodsIn this systematic review and meta-analysis, we will search Web of Science, Embase, PubMed, Wanfang Data, Medline, Science Direct, Cochrane Library through April, 2021. The protocol was written following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols. Data extraction was performed independently and only randomized clinical trials were included in this study. The risk of bias assessment was performed using the tool recommended in the Cochrane Handbook for Systematic Reviews of Interventions. All calculations were carried out with Stata 11.0 (The Cochrane Collaboration, Oxford, United Kingdom).ResultsWe hypothesized that H pylori eradication therapy compared to no eradication therapy has a statistically significant benefit for symptom relief and can also reduce the development of peptic ulcer disease.ConclusionThis study expects to provide credible and scientific evidence for the efficacy of H pylori eradication therapy for patients with FD.Osf Registration Number10.17605/OSF.IO/4EHRB.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

18 keywords...

hide…